Abstract
Nivolumab plus ipilimumab achieves higher response rates than previously reported for nivolumab alone.
©2018 American Association for Cancer Research.
MeSH terms
-
Antibodies, Monoclonal
-
Antineoplastic Combined Chemotherapy Protocols
-
Colorectal Neoplasms*
-
DNA Mismatch Repair
-
Humans
-
Ipilimumab
-
Microsatellite Instability
-
Nivolumab*
Substances
-
Antibodies, Monoclonal
-
Ipilimumab
-
Nivolumab